{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T08:19:27Z","timestamp":1793521167791,"version":"4.5.0"},"reference-count":167,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk AS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ekir.2026.106712","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T23:58:18Z","timestamp":1784678298000},"page":"106712","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Targeting Interleukin-6 for Treatment of CKD and Cardiovascular Disease"],"prefix":"10.1016","volume":"11","author":[{"given":"Katherine R.","family":"Tuttle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Z.","family":"Cherney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Pecoits-Filho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Pirro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Yau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manisha","family":"Sahay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2026.106712_bib1","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/S0140-6736(25)01853-7","article-title":"Global, regional, and national burden of chronic kidney disease in adults, 1990\u20132023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023","volume":"406","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2026.106712_bib2","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1016\/S0140-6736(18)31694-5","article-title":"Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016\u201340 for 195 countries and territories","volume":"392","author":"Foreman","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2026.106712_bib3","article-title":"The bidirectional link between diabetes and kidney disease: mechanisms and management","volume":"15","author":"Kumar","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.ekir.2026.106712_bib4","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s40265-019-1064-1","article-title":"Management of hypertension in chronic kidney disease","volume":"79","author":"Pugh","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.ekir.2026.106712_bib5","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.2215\/CJN.11491116","article-title":"Diabetic kidney disease: challenges, progress, and possibilities","volume":"12","author":"Alicic","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.106712_bib6","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ekir.2026.106712_bib7","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1161\/CIRCULATIONAHA.120.050686","article-title":"Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options","volume":"143","author":"Jankowski","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.ekir.2026.106712_bib8","series-title":"CVD risk assessment and management: what are the risk factors?","year":"2025"},{"key":"10.1016\/j.ekir.2026.106712_bib9","doi-asserted-by":"crossref","first-page":"246","DOI":"10.3390\/kidneydial4040020","article-title":"Dyslipidemia and development of chronic kidney disease in non-diabetic Japanese adults: a 26-year, community-based, longitudinal study","volume":"4","author":"Okawa","year":"2024","journal-title":"Kidney Dial"},{"key":"10.1016\/j.ekir.2026.106712_bib10","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1001\/archinte.166.17.1884","article-title":"Cardiovascular disease risk factors in chronic kidney disease: overall burden and rates of treatment and control","volume":"166","author":"Parikh","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ekir.2026.106712_bib11","doi-asserted-by":"crossref","DOI":"10.15420\/ecr.2025.33","article-title":"Obesity and chronic kidney disease: the dual epidemic in cardiovascular health","volume":"20","author":"Grant","year":"2025","journal-title":"Eur Cardiol"},{"key":"10.1016\/j.ekir.2026.106712_bib12","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1159\/000541076","article-title":"Association of arterial stiffness with chronic kidney disease: a systematic review","volume":"49","author":"Beros","year":"2024","journal-title":"Kidney Blood Press Res"},{"key":"10.1016\/j.ekir.2026.106712_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vph.2015.11.083","article-title":"Arterial stiffness, atherosclerosis and cardiovascular risk: pathophysiologic mechanisms and emerging clinical indications","volume":"77","author":"Palombo","year":"2016","journal-title":"Vascul Pharmacol"},{"key":"10.1016\/j.ekir.2026.106712_bib14","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","year":"2024","journal-title":"Kidney Int"},{"issue":"Suppl 1","key":"10.1016\/j.ekir.2026.106712_bib15","article-title":"Prevalence and characteristics of systemic inflammation in adults with atherosclerotic cardiovascular disease and chronic kidney disease: results from the national health and nutrition examination survey","volume":"146","author":"Nanna","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.ekir.2026.106712_bib17","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.007209","article-title":"Hemoglobin, albuminuria, and kidney function in cardiovascular risk: the ARIC (Atherosclerosis Risk in Communities) study","volume":"7","author":"Ishigami","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ekir.2026.106712_bib18","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1002\/ejhf.1968","article-title":"Acceleration of kidney function decline after incident hospitalization with cardiovascular disease: the Stockholm CREAtinine Measurements (SCREAM) project","volume":"22","author":"Ishigami","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ekir.2026.106712_bib19","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.3390\/biomedicines11092398","article-title":"Epidemiology and risk factors for stroke in chronic kidney disease: a narrative review","volume":"11","author":"Kourtidou","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.ekir.2026.106712_bib20","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1001\/jama.2023.17002","article-title":"Estimated glomerular filtration rate, albuminuria, and adverse outcomes: an individual-participant data meta-analysis","volume":"330","author":"Grams","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.ekir.2026.106712_bib21","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1016\/j.jacc.2011.07.010","article-title":"Chronic kidney disease and risk for presenting with acute myocardial infarction versus stable exertional angina in adults with coronary heart disease","volume":"58","author":"Go","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ekir.2026.106712_bib22","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1681\/ASN.2005111204","article-title":"Kidney function and risk of peripheral arterial disease: results from the Atherosclerosis Risk in Communities (ARIC) Study","volume":"18","author":"Wattanakit","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.106712_bib23","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1093\/eurheartj\/ehy060","article-title":"Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: improving Global Outcomes (KDIGO) Controversies Conference","volume":"39","author":"Turakhia","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ekir.2026.106712_bib24","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.2215\/CJN.02980322","article-title":"Moving from Evidence to Implementation of Breakthrough Therapies for Diabetic Kidney Disease","volume":"17","author":"Tuttle","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.106712_bib25","series-title":"Patient survival and maintenance dialysis: UpToDate","author":"Burkart","year":"2025"},{"key":"10.1016\/j.ekir.2026.106712_bib26","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1016\/S0140-6736(12)61350-6","article-title":"Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis","volume":"380","author":"Fox","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2026.106712_bib27","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1681\/ASN.2012070718","article-title":"Kidney disease and increased mortality risk in type 2 diabetes","volume":"24","author":"Afkarian","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.106712_bib28","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1001\/jama.286.3.327","article-title":"C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus","volume":"286","author":"Pradhan","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.ekir.2026.106712_bib29","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1001\/archinte.163.1.93","article-title":"C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men: results from the Monica Augsburg cohort study, 1984\u20131998","volume":"163","author":"Thorand","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ekir.2026.106712_bib30","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.dsx.2018.11.061","article-title":"Inflammatory markers and control of type 2 diabetes mellitus","volume":"13","author":"Elimam","year":"2019","journal-title":"Diabetes Metab Syndr"},{"key":"10.1016\/j.ekir.2026.106712_bib31","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1161\/hy0202.104270","article-title":"Association between pulse pressure and C-reactive protein among apparently healthy US adults","volume":"39","author":"Abramson","year":"2002","journal-title":"Hypertension"},{"key":"10.1016\/j.ekir.2026.106712_bib32","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/sj.jhh.1001785","article-title":"Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-alpha) and essential hypertension","volume":"19","author":"Bautista","year":"2005","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.ekir.2026.106712_bib33","first-page":"796","article-title":"Dietary inflammatory index and blood inflammatory markers in relation to dyslipidemia: a cross-sectional NHANES study (2009\u20132018)","volume":"34","author":"Hu","year":"2025","journal-title":"Asia Pac J Clin Nutr"},{"key":"10.1016\/j.ekir.2026.106712_bib34","doi-asserted-by":"crossref","first-page":"7381","DOI":"10.1038\/s41598-021-86336-6","article-title":"Association of baseline as well as change in lipid levels with the risk of cardiovascular diseases and all-cause deaths","volume":"11","author":"Hsu","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.ekir.2026.106712_bib35","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/2180373","article-title":"Inflammation-related mechanisms in chronic kidney disease prediction, progression, and outcome","volume":"2018","author":"Mihai","year":"2018","journal-title":"J Immunol Res"},{"key":"10.1016\/j.ekir.2026.106712_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2020.100130","article-title":"Inflammation and cardiovascular disease: from mechanisms to therapeutics","volume":"4","author":"Alfaddagh","year":"2020","journal-title":"Am J Prev Cardiol"},{"key":"10.1016\/j.ekir.2026.106712_bib37","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.2741\/3467","article-title":"NF-kappaB signalling in chronic kidney disease","volume":"14","author":"Rangan","year":"2009","journal-title":"Front Biosci (Landmark Ed)"},{"key":"10.1016\/j.ekir.2026.106712_bib38","article-title":"The nuclear factor kappa B signaling pathway is a master regulator of renal fibrosis","volume":"14","author":"Ren","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ekir.2026.106712_bib39","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1093\/ndt\/gfz082","article-title":"Renal monocyte chemoattractant protein-1: an emerging universal biomarker and therapeutic target for kidney diseases?","volume":"35","author":"Tam","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2026.106712_bib40","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1111\/j.1523-1755.2005.09911.x","article-title":"The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease","volume":"99","author":"Remuzzi","year":"2005","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.ekir.2026.106712_bib41","article-title":"The gut-kidney axis in chronic kidney disease: mechanisms, microbial metabolites, and microbiome-targeted therapeutics","volume":"12","author":"Alobaidi","year":"2025","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.ekir.2026.106712_bib42","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/s41577-024-01103-8","article-title":"Adipokines: masterminds of metabolic inflammation","volume":"25","author":"Tilg","year":"2025","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.ekir.2026.106712_bib43","article-title":"Adipose tissue metabolic changes in chronic kidney disease","volume":"5","author":"Serrano","year":"2023","journal-title":"Immunometabolism (Cobham)"},{"key":"10.1016\/j.ekir.2026.106712_bib44","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1681\/ASN.0000000591","article-title":"Autonomic dysfunction and inflammation in CKD: a high-risk pathway","volume":"36","author":"Zoccali","year":"2025","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.106712_bib45","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1093\/ndt\/gfaf020","article-title":"The autonomic nervous system and inflammation in chronic kidney disease","volume":"40","author":"Zoccali","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2026.106712_bib46","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00441-020-03351-1","article-title":"Immune regulation in renal inflammation","volume":"385","author":"Neumann","year":"2021","journal-title":"Cell Tissue Res"},{"key":"10.1016\/j.ekir.2026.106712_bib47","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/s41581-023-00766-1","article-title":"The role of complement in kidney disease","volume":"19","author":"Petr","year":"2023","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.ekir.2026.106712_bib48","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.666638","article-title":"Anemia of chronic disease in patients with cardiovascular disease","volume":"8","author":"Lanser","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.ekir.2026.106712_bib49","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1093\/ckj\/sfac240","article-title":"Prevalence of anaemia in adults with chronic kidney disease in a representative sample of the United States population: analysis of the 1999\u20132018 National Health and Nutrition Examination Survey","volume":"16","author":"Kovesdy","year":"2023","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ekir.2026.106712_bib50","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1681\/ASN.2019020213","article-title":"Iron deficiency in chronic kidney disease: updates on pathophysiology, diagnosis, and treatment","volume":"31","author":"Batchelor","year":"2020","journal-title":"J Am Soc Nephrol"},{"issue":"Suppl 3","key":"10.1016\/j.ekir.2026.106712_bib51","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/oxfordjournals.ndt.a027970","article-title":"Pathophysiology of anaemia: focus on the heart and blood vessels","volume":"15","author":"Metivier","year":"2000","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2026.106712_bib52","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1093\/intimm\/dxaa078","article-title":"IL-6 in inflammation, autoimmunity and cancer","volume":"33","author":"Hirano","year":"2021","journal-title":"Int Immunol"},{"key":"10.1016\/j.ekir.2026.106712_bib53","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1080\/1744666X.2022.2045952","article-title":"Interleukin 6 in diabetes, chronic kidney disease, and cardiovascular disease: mechanisms and therapeutic perspectives","volume":"18","author":"Kreiner","year":"2022","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.ekir.2026.106712_bib54","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s12265-020-10049-w","article-title":"Immunomodulation of the NLRP3 inflammasome in atherosclerosis, coronary artery disease, and acute myocardial infarction","volume":"14","author":"Silvis","year":"2021","journal-title":"J Cardiovasc Transl Res"},{"key":"10.1016\/j.ekir.2026.106712_bib55","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1161\/CIRCULATIONAHA.119.045256","article-title":"From CANTOS to CIRT to COLCOT to clinic: will all atherosclerosis patients soon be treated with combination lipid-lowering and inflammation-inhibiting agents?","volume":"141","author":"Ridker","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.ekir.2026.106712_bib56","article-title":"Chronic kidney disease and NLRP3 inflammasome: pathogenesis, development and targeted therapeutic strategies","volume":"33","author":"Huang","year":"2023","journal-title":"Biochem Biophys Rep"},{"key":"10.1016\/j.ekir.2026.106712_bib57","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1161\/CIRCRESAHA.121.319077","article-title":"Interleukin-6 signaling and anti-interleukin-6 therapeutics in cardiovascular disease","volume":"128","author":"Ridker","year":"2021","journal-title":"Circ Res"},{"key":"10.1016\/j.ekir.2026.106712_bib58","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/s41577-023-00856-y","article-title":"Targeting IL-6 trans-signalling: past, present and future prospects","volume":"23","author":"Rose-John","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.ekir.2026.106712_bib59","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.641734","article-title":"Role of interleukin-6 in vascular health and disease","volume":"8","author":"Villar-Fincheira","year":"2021","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.ekir.2026.106712_bib60","doi-asserted-by":"crossref","first-page":"405","DOI":"10.3389\/fimmu.2017.00405","article-title":"Interleukin-6 signaling pathway and its role in kidney disease: an update","volume":"8","author":"Su","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.ekir.2026.106712_bib61","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.bbamcr.2011.01.034","article-title":"The pro- and anti-inflammatory properties of the cytokine interleukin-6","volume":"1813","author":"Scheller","year":"2011","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.ekir.2026.106712_bib62","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.3390\/ijms26073072","article-title":"Targeting inflammatory imbalance in chronic kidney disease: focus on anti-inflammatory and resolution mediators","volume":"26","author":"Rispoli","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ekir.2026.106712_bib63","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/s41581-022-00621-9","article-title":"Targeting innate immunity-driven inflammation in CKD and cardiovascular disease","volume":"18","author":"Speer","year":"2022","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.ekir.2026.106712_bib64","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41420-024-01996-3","article-title":"Renal macrophages and NLRP3 inflammasomes in kidney diseases and therapeutics","volume":"10","author":"Islamuddin","year":"2024","journal-title":"Cell Death Discov"},{"key":"10.1016\/j.ekir.2026.106712_bib65","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1159\/000097667","article-title":"Increased glucose uptake and metabolism in mesangial cells overexpressing glucose transporter 1 increases interleukin-6 and vascular endothelial growth factor production: role of AP-1 and HIF-1alpha","volume":"18","author":"Pfafflin","year":"2006","journal-title":"Cell Physiol Biochem"},{"key":"10.1016\/j.ekir.2026.106712_bib66","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/6357046","article-title":"CD154 induces interleukin-6 secretion by kidney tubular epithelial cells under hypoxic conditions: inhibition by chloroquine","volume":"2020","author":"Dewitte","year":"2020","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.ekir.2026.106712_bib67","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1502299","article-title":"Targeting inerleukin-6 for renoprotection","volume":"15","author":"Gubernatorova","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.ekir.2026.106712_bib68","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1161\/HYPERTENSIONAHA.111.173328","article-title":"Interleukin 6 underlies angiotensin II-induced hypertension and chronic renal damage","volume":"59","author":"Zhang","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.ekir.2026.106712_bib69","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.3390\/ijms24043427","article-title":"Endothelin receptor antagonists in kidney disease","volume":"24","author":"Martinez-Diaz","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ekir.2026.106712_bib70","doi-asserted-by":"crossref","DOI":"10.1093\/eurjpc\/zwag088","article-title":"Interleukin-6 and the inflammatory origins of chronic kidney disease","author":"Chang","year":"2026","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.ekir.2026.106712_bib71","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/labinvest.2013.85","article-title":"Chronic administration of EP4-selective agonist exacerbates albuminuria and fibrosis of the kidney in streptozotocin-induced diabetic mice through IL-6","volume":"93","author":"Mohamed","year":"2013","journal-title":"Lab Investig"},{"key":"10.1016\/j.ekir.2026.106712_bib72","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1082492","article-title":"Correlation analysis of serum IGF-1 and IL-6 and urinary albumin\/creatinine ratio in patients with type 2 diabetic kidney disease","volume":"13","author":"Liu","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.ekir.2026.106712_bib73","first-page":"1","article-title":"Correlation between serum biomarkers and disease progression of chronic kidney disease","volume":"85","author":"Xu","year":"2024","journal-title":"Br J Hosp Med (Lond)"},{"key":"10.1016\/j.ekir.2026.106712_bib74","doi-asserted-by":"crossref","first-page":"384","DOI":"10.3390\/toxins10100384","article-title":"The impact of uremic toxicity induced inflammatory response on the cardiovascular burden in chronic kidney disease","volume":"10","author":"Claro","year":"2018","journal-title":"Toxins (Basel)"},{"key":"10.1016\/j.ekir.2026.106712_bib75","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1093\/eurheartj\/ehp574","article-title":"Does indoxyl sulfate, a uraemic toxin, have direct effects on cardiac fibroblasts and myocytes?","volume":"31","author":"Lekawanvijit","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ekir.2026.106712_bib76","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.arcmed.2014.04.002","article-title":"Protein-bound uremic toxins, inflammation and oxidative stress: a cross-sectional study in stage 3\u20134 chronic kidney disease","volume":"45","author":"Rossi","year":"2014","journal-title":"Arch Med Res"},{"key":"10.1016\/j.ekir.2026.106712_bib77","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/s41581-018-0018-2","article-title":"The gut microbiota and the brain-gut-kidney axis in hypertension and chronic kidney disease","volume":"14","author":"Yang","year":"2018","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.ekir.2026.106712_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.114984","article-title":"Uremic toxins activate CREB\/ATF1 in endothelial cells related to chronic kidney disease","volume":"198","author":"Stafim da Cunha","year":"2022","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.ekir.2026.106712_bib79","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1124\/pharmrev.120.000096","article-title":"Endothelial dysfunction in atherosclerotic cardiovascular diseases and beyond: from mechanism to pharmacotherapies","volume":"73","author":"Xu","year":"2021","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.ekir.2026.106712_bib80","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfaf223","article-title":"New biomarkers of inflammation associated with haemodialysis","volume":"18","author":"Guerrero","year":"2025","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ekir.2026.106712_bib81","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3390\/toxins16050227","article-title":"A historical perspective on uremia and uremic toxins","volume":"16","author":"Meijers","year":"2024","journal-title":"Toxins (Basel)"},{"key":"10.1016\/j.ekir.2026.106712_bib82","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.3390\/jpm12071122","article-title":"The role of plasma interleukin-6 levels on atherosclerotic cardiovascular disease and cardiovascular mortality risk scores in Javanese patients with chronic kidney disease","volume":"12","author":"Susilo","year":"2022","journal-title":"J Pers Med"},{"key":"10.1016\/j.ekir.2026.106712_bib83","doi-asserted-by":"crossref","DOI":"10.1111\/eci.70161","article-title":"IL-6 in the spotlight: from cardiovascular pathophysiology to therapy","volume":"56","author":"Preda","year":"2026","journal-title":"Eur J Clin Investig"},{"key":"10.1016\/j.ekir.2026.106712_bib84","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1161\/01.RES.0000115557.25127.8D","article-title":"Interleukin-6 induces oxidative stress and endothelial dysfunction by overexpression of the angiotensin II type 1 receptor","volume":"94","author":"Wassmann","year":"2004","journal-title":"Circ Res"},{"key":"10.1016\/j.ekir.2026.106712_bib85","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1161\/hc0302.102618","article-title":"The AT(1)-type angiotensin receptor in oxidative stress and atherogenesis: part I: Oxidative stress and atherogenesis","volume":"105","author":"Nickenig","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.ekir.2026.106712_bib86","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1182\/blood.V91.1.258","article-title":"Interleukin-6 induces monocyte chemotactic Protein-1 in peripheral blood mononuclear cells and in the U937 cell line","volume":"91","author":"Biswas","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2026.106712_bib87","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/7434376","article-title":"The role of monocytes and macrophages in human atherosclerosis, plaque neoangiogenesis, and atherothrombosis","volume":"2019","author":"Moroni","year":"2019","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.ekir.2026.106712_bib88","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1046\/j.1365-2141.2000.02020.x","article-title":"Activity of interleukin 6 in the differentiation of monocytes to macrophages and dendritic cells","volume":"109","author":"Mitani","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ekir.2026.106712_bib89","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1182\/blood.V74.4.1241.1241","article-title":"Interleukin-6 is a potent thrombopoietic factor in vivo in mice","volume":"74","author":"Ishibashi","year":"1989","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2026.106712_bib90","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1182\/blood.V98.9.2720","article-title":"Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis","volume":"98","author":"Kaser","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2026.106712_bib91","doi-asserted-by":"crossref","first-page":"766","DOI":"10.3390\/cells14110766","article-title":"IL-6 as a mediator of platelet hyper-responsiveness","volume":"14","author":"Webb","year":"2025","journal-title":"Cells"},{"key":"10.1016\/j.ekir.2026.106712_bib92","doi-asserted-by":"crossref","first-page":"E527","DOI":"10.1152\/ajpendo.00110.2003","article-title":"Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans","volume":"285","author":"Bruun","year":"2003","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.ekir.2026.106712_bib93","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S0006-291X(03)00090-1","article-title":"Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes","volume":"301","author":"Fasshauer","year":"2003","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.ekir.2026.106712_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2025.100950","article-title":"Prevalence and clinical characteristics of patients with hsCRP testing and test-confirmed systemic inflammation among individuals with atherosclerotic cardiovascular disease with or without chronic kidney disease in the United States (Plutus)","volume":"21","author":"Lv","year":"2025","journal-title":"Am J Prev Cardiol"},{"issue":"Suppl 2","key":"10.1016\/j.ekir.2026.106712_bib95","article-title":"Prevalence of systemic inflammation in individuals with atherosclerotic cardiovascular disease: baseline characteristics from the SELECT, SOUL and FLOW phase 3 trials of semaglutide","volume":"44","author":"Marx","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ekir.2026.106712_bib96","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2025.1538466","article-title":"Systemic inflammation prevalence in patients with atherosclerotic cardiovascular disease and chronic kidney disease: a population-based study using a nationwide primary care database in Spain","volume":"12","author":"Pesce","year":"2025","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.ekir.2026.106712_bib97","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1111\/j.1523-1755.2004.00465.x","article-title":"Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease","volume":"65","author":"Oberg","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.106712_bib98","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/j.1523-1755.2005.00455.x","article-title":"C-reactive protein and albumin as predictors of all-cause and cardiovascular mortality in chronic kidney disease","volume":"68","author":"Menon","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.106712_bib99","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1001\/jamacardio.2021.3079","article-title":"Interleukin 6 and cardiovascular outcomes in patients with chronic kidney disease and chronic coronary syndrome","volume":"6","author":"Batra","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"Suppl 1","key":"10.1016\/j.ekir.2026.106712_bib100","first-page":"2740","article-title":"Systemic inflammation and risk of death in patients with atherosclerotic cardiovascular disease and chronic kidney disease","volume":"45","author":"Rudolfsen","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ekir.2026.106712_bib101","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1053\/j.ajkd.2018.09.012","article-title":"Use of measures of inflammation and kidney function for prediction of atherosclerotic vascular disease events and death in patients with CKD: findings from the CRIC study","volume":"73","author":"Amdur","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2026.106712_bib102","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.2337\/dc22-0866","article-title":"Interleukin-6 and cardiovascular and kidney outcomes in patients with type 2 diabetes: new insights from CANVAS","volume":"45","author":"Koshino","year":"2022","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"10.1016\/j.ekir.2026.106712_bib103","first-page":"1300","article-title":"Burden of systemic inflammation and associated health outcomes in adults with atherosclerotic cardiovascular disease managed in routine care","volume":"45","author":"Mazhar","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ekir.2026.106712_bib104","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1053\/j.ajkd.2025.04.011","article-title":"Systemic inflammation and the risks of adverse kidney outcomes in adults with atherosclerotic cardiovascular disease","volume":"86","author":"Mazhar","year":"2025","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2026.106712_bib105","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1093\/eurjpc\/zwaf779","article-title":"The role of inflammation in longitudinal renal function decline and incident chronic kidney disease: the multi-ethnic study of atherosclerosis","volume":"33","author":"Agboola","year":"2026","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.ekir.2026.106712_bib106","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/7692376","article-title":"The impact of CKD anaemia on patients: incidence, risk factors, and clinical outcomes-A systematic literature review","volume":"2020","author":"Palaka","year":"2020","journal-title":"Int J Nephrol"},{"key":"10.1016\/j.ekir.2026.106712_bib107","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/1471-2261-9-51","article-title":"The impact of renal insufficiency and anaemia on survival in patients with cardiovascular disease: a cohort study","volume":"9","author":"Anderson","year":"2009","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.ekir.2026.106712_bib108","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1007\/s00380-021-01794-2","article-title":"The prognostic implications of chronic kidney disease and anemia on long-term outcomes in patients undergoing percutaneous coronary intervention","volume":"36","author":"Takeuchi","year":"2021","journal-title":"Heart Vessels"},{"key":"10.1016\/j.ekir.2026.106712_bib109","doi-asserted-by":"crossref","first-page":"76","DOI":"10.9734\/jammr\/2022\/v34i1031356","article-title":"The role of interleukin-6. In: Anemia of Patients with Chronic Kidney Disease, in Pre-dialysis Stage","volume":"34","author":"Esmail","year":"2022","journal-title":"J Adv Med Med Res"},{"key":"10.1016\/j.ekir.2026.106712_bib110","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1093\/ndt\/gfn109","article-title":"Association of inflammation with anaemia in patients with chronic kidney disease not requiring chronic dialysis","volume":"23","author":"Chonchol","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2026.106712_bib111","doi-asserted-by":"crossref","first-page":"725","DOI":"10.3390\/ijms21030725","article-title":"The influence of inflammation on anemia in CKD patients","volume":"21","author":"Gluba-Brzozka","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ekir.2026.106712_bib112","article-title":"Iron and chronic kidney disease: still a challenge","volume":"7","author":"Wojtaszek","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.ekir.2026.106712_bib113","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0078850","article-title":"Dietary iron enhances colonic inflammation and IL-6\/IL-11-Stat3 signaling promoting colonic tumor development in mice","volume":"8","author":"Chua","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ekir.2026.106712_bib114","doi-asserted-by":"crossref","first-page":"4260","DOI":"10.1038\/s41598-017-04664-y","article-title":"Serum hepcidin may be a novel uremic toxin, which might be related to erythropoietin resistance","volume":"7","author":"Lee","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.ekir.2026.106712_bib115","first-page":"2013","article-title":"Association of malnutrition-inflammation complex and responsiveness to erythropoiesis-stimulating agents in long-term hemodialysis patients","volume":"28","author":"Rattanasompattikul","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2026.106712_bib116","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1542-4758.2011.00635.x","article-title":"IL-6 is an independent risk factor for resistance to erythropoiesis-stimulating agents in hemodialysis patients without iron deficiency","volume":"16","author":"Won","year":"2012","journal-title":"Hemodial Int"},{"key":"10.1016\/j.ekir.2026.106712_bib117","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.bcmd.2013.09.004","article-title":"Interleukin-6 directly impairs the erythroid development of human TF-1 erythroleukemic cells","volume":"52","author":"McCranor","year":"2014","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.ekir.2026.106712_bib118","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/3041738","article-title":"Effect of interleukin and hepcidin in anemia of chronic diseases","volume":"2020","author":"Yacoub","year":"2020","journal-title":"Anemia"},{"key":"10.1016\/j.ekir.2026.106712_bib119","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1681\/ASN.2015010052","article-title":"The labile side of iron supplementation in CKD","volume":"26","author":"Slotki","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.106712_bib120","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1182\/hematology.2024000655","article-title":"Hypoxia-inducible factor activators: a novel class of oral drugs for the treatment of anemia of chronic kidney disease","volume":"2024","author":"Haase","year":"2024","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.ekir.2026.106712_bib121","article-title":"Inflammation and cardiovascular disease: 2025 ACC scientific statement: a report of the American College of Cardiology","author":"Mensah","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ekir.2026.106712_bib122","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1093\/eurheartj\/ehaf190","article-title":"2025 Focused Update of the 2019 ESC\/EAS Guidelines for the management of dyslipidaemias","volume":"46","author":"Mach","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ekir.2026.106712_bib123","first-page":"2624","article-title":"2026 ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of dyslipidemia: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"87","author":"Blumenthal","year":"2026","journal-title":"Circulation"},{"key":"10.1016\/j.ekir.2026.106712_bib124","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000033984","article-title":"Comprehensive review of current management guidelines of chronic kidney disease","volume":"102","author":"Elendu","year":"2023","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ekir.2026.106712_bib125","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","volume":"41","author":"Mancia","year":"2023","journal-title":"J Hypertens"},{"key":"10.1016\/j.ekir.2026.106712_bib126","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","article-title":"2024 ESC Guidelines for the management of elevated blood pressure and hypertension","volume":"45","author":"McEvoy","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ekir.2026.106712_bib127","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1053\/j.ajkd.2015.10.011","article-title":"Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a Bayesian network meta-analysis of randomized clinical trials","volume":"67","author":"Xie","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2026.106712_bib128","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.030131","article-title":"Albuminuria: an underappreciated risk factor for cardiovascular disease","volume":"13","author":"Barzilay","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ekir.2026.106712_bib129","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.106712_bib130","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1053\/j.ackd.2017.12.002","article-title":"Inflammatory mechanisms as new biomarkers and therapeutic targets for diabetic kidney disease","volume":"25","author":"Alicic","year":"2018","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.ekir.2026.106712_bib131","doi-asserted-by":"crossref","first-page":"F716","DOI":"10.1152\/ajprenal.00314.2016","article-title":"Immunity and inflammation in diabetic kidney disease: translating mechanisms to biomarkers and treatment targets","volume":"312","author":"Pichler","year":"2017","journal-title":"Am J Physiol Ren Physiol"},{"key":"10.1016\/j.ekir.2026.106712_bib132","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1093\/cvr\/cvy293","article-title":"Identifying the anti-inflammatory response to lipid lowering therapy: a position paper from the working group on atherosclerosis and vascular biology of the European Society of Cardiology","volume":"115","author":"Tunon","year":"2019","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.ekir.2026.106712_bib133","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1161\/01.ATV.21.1.115","article-title":"Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering","volume":"21","author":"Sparrow","year":"2001","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ekir.2026.106712_bib134","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.4049\/jimmunol.170.3.1524","article-title":"A novel anti-inflammatory role for simvastatin in inflammatory arthritis","volume":"170","author":"Leung","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.ekir.2026.106712_bib135","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1002\/jcp.27205","article-title":"The potential therapeutic use of renin-angiotensin system inhibitors in the treatment of inflammatory diseases","volume":"234","author":"Ranjbar","year":"2019","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.ekir.2026.106712_bib136","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1016\/j.mayocp.2022.06.036","article-title":"Effect of the renin-angiotensin system inhibitors on inflammatory markers: a systematic review and meta-analysis of randomized controlled trials","volume":"97","author":"Awad","year":"2022","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ekir.2026.106712_bib137","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0329965","article-title":"Effect of finerenone on urinary protein and inflammatory factor levels in type 2 diabetes mellitus patients with diabetic kidney disease","volume":"20","author":"Song","year":"2025","journal-title":"PLoS One"},{"key":"10.1016\/j.ekir.2026.106712_bib138","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.2337\/dc09-2361","article-title":"Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition","volume":"33","author":"Bunck","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ekir.2026.106712_bib139","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1210\/jc.2011-1508","article-title":"Exenatide exerts a potent antiinflammatory effect","volume":"97","author":"Chaudhuri","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ekir.2026.106712_bib140","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.cmet.2023.11.009","article-title":"Central glucagon-like peptide 1 receptor activation inhibits toll-like receptor agonist-induced inflammation","volume":"36","author":"Wong","year":"2024","journal-title":"Cell Metab"},{"key":"10.1016\/j.ekir.2026.106712_bib141","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s00125-013-3145-0","article-title":"Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus","volume":"57","author":"Hogan","year":"2014","journal-title":"Diabetologia"},{"key":"10.1016\/j.ekir.2026.106712_bib142","doi-asserted-by":"crossref","DOI":"10.1177\/11795468251347777","article-title":"Evaluating the safety and efficacy of SGLT-2 inhibitors on reducing cardiovascular and renal mortality, morbidity and inflammatory outcomes in various patient populations: a systematic review and meta-analysis of 92 920 patients","volume":"19","author":"Haider","year":"2025","journal-title":"Clin Med Insights Cardiol"},{"key":"10.1016\/j.ekir.2026.106712_bib143","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1681\/ASN.2018121231","article-title":"Effects of selonsertib in patients with diabetic kidney disease","volume":"30","author":"Chertow","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.106712_bib144","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1681\/ASN.0000000000000444","article-title":"Selonsertib in patients with diabetic kidney disease: a Phase 2b randomized active run-in clinical trial","volume":"35","author":"Heerspink","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.106712_bib145","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1056\/NEJMoa1306033","article-title":"Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease","volume":"369","author":"de Zeeuw","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.106712_bib146","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJMoa1105351","article-title":"Bardoxolone methyl and kidney function in CKD with type 2 diabetes","volume":"365","author":"Pergola","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.106712_bib147","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.2337\/diacare.28.11.2686","article-title":"The effect of Ruboxistaurin on nephropathy in type 2 diabetes","volume":"28","author":"Tuttle","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ekir.2026.106712_bib148","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2215\/CJN.00840207","article-title":"Kidney outcomes in long-term studies of Ruboxistaurin for diabetic eye disease","volume":"2","author":"Tuttle","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.106712_bib149","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1007\/s00125-016-4021-5","article-title":"JAK inhibition in the treatment of diabetic kidney disease","volume":"59","author":"Brosius","year":"2016","journal-title":"Diabetologia"},{"key":"10.1016\/j.ekir.2026.106712_bib150","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1093\/ndt\/gfx377","article-title":"JAK1\/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial","volume":"33","author":"Tuttle","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2026.106712_bib151","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1681\/ASN.2014010012","article-title":"Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial","volume":"26","author":"Navarro-Gonzalez","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.106712_bib152","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1007\/s12325-017-0547-2","article-title":"Repurposing pentoxifylline for the treatment of fibrosis: an overview","volume":"34","author":"Wen","year":"2017","journal-title":"Adv Ther"},{"key":"10.1016\/j.ekir.2026.106712_bib153","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1016\/j.ekir.2024.06.033","article-title":"Design and rationale of the Phase 2 baricitinib study in apolipoprotein L1-mediated kidney disease (JUSTICE)","volume":"9","author":"Olabisi","year":"2024","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2026.106712_bib154","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1053\/j.ajkd.2025.06.019","article-title":"Targeting inflammation in CKD","volume":"86","author":"Nowak","year":"2025","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2026.106712_bib155","series-title":"Colchicine 500 microgram tablets. Summary of product characteristics: Datapharm","year":"2025"},{"key":"10.1016\/j.ekir.2026.106712_bib156","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/35013070","article-title":"Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin","volume":"405","author":"Borovikova","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.ekir.2026.106712_bib157","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1093\/eurheartj\/ehy310","article-title":"Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS)","volume":"39","author":"Ridker","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ekir.2026.106712_bib158","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1136\/heartjnl-2013-303648","article-title":"Cardiovascular effects of tumour necrosis factor alpha antagonism in patients with acute myocardial infarction: a first in human study","volume":"99","author":"Padfield","year":"2013","journal-title":"Heart"},{"key":"10.1016\/j.ekir.2026.106712_bib159","doi-asserted-by":"crossref","first-page":"681","DOI":"10.2147\/ITT.S485684","article-title":"IL-6 signaling in immunopathology: from basic biology to selective therapeutic intervention","volume":"14","author":"Schumertl","year":"2025","journal-title":"ImmunoTargets Ther"},{"key":"10.1016\/j.ekir.2026.106712_bib160","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1681\/ASN.0000000000000245","article-title":"Effect of ziltivekimab on determinants of hemoglobin in patients with CKD Stage 3\u20135: an analysis of a randomized trial (RESCUE)","volume":"35","author":"Pergola","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.106712_bib161","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1016\/S0140-6736(21)00520-1","article-title":"IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"397","author":"Ridker","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2026.106712_bib162","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.jjcc.2023.05.006","article-title":"Efficacy and safety of interleukin-6 inhibition with ziltivekimab in patients at high risk of atherosclerotic events in Japan (RESCUE-2): a randomized, double-blind, placebo-controlled, phase 2 trial","volume":"82","author":"Wada","year":"2023","journal-title":"J Cardiol"},{"key":"10.1016\/j.ekir.2026.106712_bib163","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1038\/s41591-024-03043-1","article-title":"IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial","volume":"30","author":"Chertow","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.ekir.2026.106712_bib165","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1080\/17512433.2022.2097905","article-title":"Current status and prospects of IL-6-targeting therapy","volume":"15","author":"Narazaki","year":"2022","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.ekir.2026.106712_bib169","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1136\/annrheumdis-2012-202469","article-title":"Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions","volume":"72","author":"Smolen","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ekir.2026.106712_bib170","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1023177","article-title":"The role of IL-6\/JAK2\/STAT3 signaling pathway in cancers","volume":"12","author":"Huang","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.ekir.2026.106712_bib171","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1136\/annrheumdis-2021-221244","article-title":"Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases","volume":"80","author":"Friedman","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ekir.2026.106712_bib172","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfaf001","article-title":"Effects of anti-inflammatory agents on clinical outcomes in people with chronic kidney disease: a systematic review and meta-analysis of randomized control trials","volume":"18","author":"Webster","year":"2025","journal-title":"Clin Kidney J"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S246802492602944X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S246802492602944X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T09:41:43Z","timestamp":1790934103000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S246802492602944X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":167,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S246802492602944X"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2026.106712","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting Interleukin-6 for Treatment of CKD and Cardiovascular Disease","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2026.106712","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of the International Society of Nephrology.","name":"copyright","label":"Copyright"}],"article-number":"106712"}}